Patents by Inventor Christine M. Tarby

Christine M. Tarby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230348468
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). (I) (II) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: November 2, 2023
    Inventors: Matthew COX, Naidu S. CHOWDARI, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Christine M. TARBY, Yam B. POUDEL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • URACIL DERIVATIVES AS MER-AXL INHIBITORS
    Publication number: 20230339891
    Abstract: The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 26, 2023
    Inventors: Christine M. Tarby, Derek J. Norris, Julian C. Lo, Vijay T. Ahuja, Steven P. Seitz, Ashvinikumar V. Gavai, John S. Tokarski, Mohini Rajasagi, Michael Wichroski, Matthias Broekema
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230144824
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 11, 2023
    Inventors: Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Qiang CONG, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Christine M. TARBY, Patrice GILL, Andrew F. DONNELL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230140430
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 4, 2023
    Inventors: Matthew COX, Liqi HE, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Matthias BROEKEMA, Qiang CONG, Daniel O'MALLEY, Yam B. POUDEL, Christine M. TARBY
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR
    Publication number: 20230140047
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: December 14, 2022
    Publication date: May 4, 2023
    Inventors: YAM B. POUDEL, Sanjeev GANGWAR, Liqi HE, Prasanna SIVAPRAKASAM, Matthias BROEKEMA, Matthew COX, Christine M. TARBY, Qian ZHANG, Naidu S. CHOWDARI
  • C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230127326
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Qiang CONG, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Patrice GILL, Prasanna SIVAPRAKASAM, Walter L. JOHNSON, Murugaiah Andappan Murugaiah SUBBAIAH, Yam B. POUDEL
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230130516
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Qian ZHANG, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Qiang CONG, Yam B. POUDEL, Liqi HE, Prasanna SIVAPRAKASAM, Christine M. TARBY
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230131192
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Matthias BROEKEMA, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Naidu S. CHOWDARI, Walter L JOHNSON, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230118688
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Inventors: Heng CHENG, Christine M. TARBY, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Walter L. JOHNSON, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Patrice GILL, Andrew F. DONNELL, Murugaiah Andappan Murugaiah SUBBAIAH
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230122249
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Daniel O'MALLEY, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Prasanna SIVAPRAKASAM, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH,Murugaiah
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230041738
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: February 9, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Mathias BROEKEMA, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
    Patent number: 11554120
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 17, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Liqi He, Prasanna Sivaprakasam, Matthias Broekema, Matthew Cox, Christine M. Tarby, Qian Zhang, Naidu S. Chowdari
  • NLRP3 MODULATORS
    Publication number: 20220257587
    Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: April 28, 2022
    Publication date: August 18, 2022
    Inventors: Daniel O'Malley, Ashvinkumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • NLRP3 modulators
    Patent number: 11344543
    Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: May 31, 2022
    Assignee: Innate Tumor Immunity, Inc.
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • NLRP3 MODULATORS
    Publication number: 20220087991
    Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 20, 2020
    Publication date: March 24, 2022
    Inventors: Scott Hunter Watterson, Daniel O'Malley, Ashvinikumar V. Gavai, Hua Gong, Christine M. Tarby
  • NLRP3 MODULATORS
    Publication number: 20220089572
    Abstract: The present invention provides compounds of Formula (I):(I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Inventors: Ashvinikumar V. Gavai, Derek J. Norris, Daniel O'MALLEY, Steven P. Seitz, Jay A. Markwalder, David K. Williams, Hua Gong, Scott Hunter Watterson, Christine M. Tarby
  • NLRP3 MODULATORS
    Publication number: 20220089571
    Abstract: The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Derek J. Norris, Hua Gong, Yong Zhang, Patrice Gill, Christine M. Tarby, Matthias Broekema, Scott Hunter Watterson
  • NLRP3 MODULATORS
    Publication number: 20200129500
    Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: July 12, 2018
    Publication date: April 30, 2020
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR
    Publication number: 20200038403
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Yam B. POUDEL, Sanjeev GANGWAR, Liqi HE, Prasanna SIVAPRAKASAM, Matthias BROEKEMA, Matthew COX, Christine M. TARBY, Qian ZHANG
  • Imidazotriazinecarbonitriles useful as kinase inhibitors
    Patent number: 9556178
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: January 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Ashvinikumar V. Gavai, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann